Tyra Biosciences, Inc. (TYRA) Stock Price & Analysis
Tyra Biosciences, Inc. (TYRA) fell 3.03% to USD 25.94 as of June 10, 2026 at 02:15 UTC, according to Nexqual real-time market data.
TYRA last closed at USD 26.75; the session ranged USD 25.22–27.29 on volume of 1,424,038 shares. Market capitalization is $1.54B, with a 52-week range of USD 8.98–40.65 (NMS). Source: Nexqual, June 10, 2026 at 02:15 UTC.
Key Statistics (as of June 10, 2026 at 02:15 UTC)
| Price | USD 25.94 |
|---|---|
| Change | ▼ 3.03% (down) |
| Previous Close | USD 26.75 |
| Open | USD 27.24 |
| Day Range | USD 25.22 – 27.29 |
| 52-Week Range | USD 8.98 – 40.65 |
| Volume | 1,424,038 shares |
| Market Cap | $1.54B |
| Exchange | NMS |
Technical Analysis (TYRA)
Nexqual's technical model rates TYRA "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:15 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 23.56 (oversold) |
| vs SMA50 | Below (USD 34.29) |
| MACD | -2.22 (negative) |
Analyst Ratings (TYRA)
Wall Street analysts rate TYRA "Strong Buy" based on 11 analysts, with a mean price target of USD 51.15 (range USD 37–59.62), per Nexqual as of June 10, 2026 at 02:15 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 51.15 |
| High Target | USD 59.62 |
| Low Target | USD 37 |
| Buy / Hold / Sell | 13 / 1 / 0 |
Earnings (TYRA)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.64 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.64 vs est -0.59 ▼ miss |
| 2025-12-31 | USD -0.57 vs est -0.53 ▼ miss |
| 2025-09-30 | USD -0.5 vs est -0.51 ▲ beat |
| 2025-06-30 | USD -0.47 vs est -0.51 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Financials & Fundamentals (TYRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -36.87% |
| Debt / Equity | 1.47 |
| Current Ratio | 20.49 |
| Total Cash | $383.47M |
| Total Debt | $5.70M |
| Free Cash Flow | $-60.14M |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Financial Health Score (TYRA)
Nexqual rates Tyra Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:15 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $383M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$102M |
| Efficiency | Critical — ROE -37%, ROA -23.6% |
Ownership (TYRA)
| Insider Ownership | +2.86% |
|---|---|
| Institutional Ownership | +111.46% |
| Shares Outstanding | 59.47M |
| Float | 30.88M |
| Short % of Float | +28.85% |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Leadership (TYRA)
Tyra Biosciences, Inc. is led by Todd Harris (age 46), Co-Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 02:15 UTC.
| Co-Founder, CEO, President & Director | Todd Harris (age 46) |
|---|---|
| Chief Operating Officer | Bhavesh Ashar (age 56) |
| Chief Financial Officer | Alan Fuhrman (age 68) |
| Chief Technology Officer | Robert L. Hudkins (age 70) |
| Chief Scientific Officer | Ronald V. Swanson (age 62) |
Major Backers & Investors (TYRA)
Notable institutional backers of Tyra Biosciences, Inc. include RA Capital Management, L.P., FMR, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 02:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 20.51% |
| FMR, LLC | 13.03% |
| Fidelity | 7.82% |
| Nextech Invest, Ltd. | 6.82% |
| Janus Henderson Group PLC | 6.54% |
| Alta Partners Management Company, L.P. | 6.43% |
| Farallon Capital Management LLC | 6.02% |
| TCG Crossover Management, LLC | 5.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.76% |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
From Tyra Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
- The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
- Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.
- The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 9.23 | ▲ 6.83% |
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 16.61 | ▲ 1.47% |
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:15 UTC. This page is informational and not investment advice.